课题基金 / 基金详情

De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptors

De novo design of generalizable allosteric modulators and peptide ligands for G protein coupled receptors
G 蛋白偶联受体的通用变构调节剂和肽配体的从头设计
批准号:
10160902
负责人:
Christopher David Bahl
金额:
$17.98万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-05-07 至 2022-01-27

项目摘要

项目成果

Christopher David Bahl的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
Project Summary Roughly one third of all FDA approved drugs target G protein coupled receptors (GPCRs), and this protein family holds myriad therapeutic opportunities yet to be discovered. GPCRs signal through allosteric changes in protein structure, and there is a large unmet need for effective, highly generalizable tools for conformational control of these receptors. ​This project has two Specific Aims, both of which employ computational protein design with Rosetta to build proteins ​de novo that bind and modulate GPCR conformation. Upon ligand binding and activation, GPCRs associate with and signal through G proteins. In the first Aim, we design proteins ​de novo which mimic the interaction domain of the endogenous Gα protein subunit. Because the interaction between receptor and Gα is highly conserved, the protein tools we propose to develop can be applied broadly. Synthetic genes encoding ​de novo Gα mimetics have been expressed, and protein was purified from Escherichia coli.​ Binding to several different detergent-solubilized GPCRs was demonstrated ​via pull-down and Western blotting. Functional Gα mimetic proteins will be structurally characterized and used as templates for re-engineering a small suite of mimetics for all Gα subtypes. Additionally, we propose to leverage the Gα mimetics to enhance the expression and purification of GPCRs. To demonstrate this system, we will attempt to produce three different GPCRs for the first time: super conserved receptor expressed in brain 1-3. In the second aim, we will design disulfide constrained peptides to serve as agonists and antagonists for all structure-enabled family B GPCRs. This receptor family recognizes endogenous peptide ligands, and they are difficult to drug with small molecules. Structures that detail ligand recognition are available for 60% of family B receptors; we will use these as the basis for ​de novo design of high-affinity antagonist ligands based on disulfide-constrained peptides. We will then screen hundreds of thousands of rationally designed ​de novo peptides using yeast display, fluorescence activated cell sorting, and deep sequencing. Our unique design approach enables us to custom tailor the peptide topology so that we can readily convert our antagonists into high affinity agonists by extending the peptide N-terminus. The efficacy of designed ligands identified ​via the high-throughput screen will be assessed individually using a luciferase reporter assay for GPCR signaling. The research proposed here represents the first time that computational ​de novo protein design will be applied to control GPCR conformation. This work has the potential to create valuable tools to empower the GPCR research community and accelerate discovery of lead therapeutics for many diseases.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.sbi.2020.10.015
发表时间: 2021-03
期刊: Current opinion in structural biology
影响因子: 6.8
作者: [Adolf-Bryfogle J, Teets FD, Bahl CD]
通讯作者: Bahl CD
Complete Combinatorial Mutational Enumeration of a protein functional site enables sequence-landscape mapping and identifies highly-mutated variants that retain activity.
蛋白质功能位点的完整组合突变枚举可实现序列景观图谱并识别保留活性的高度突变变体。
DOI: 10.21203/rs.3.rs-2248327/v1
发表时间: 2023
期刊: Research square
影响因子: --
作者: [Colom,MireiaSolà, Vucinic,Jelena, Adolf-Bryfogle,Jared, Bowman,JamesW, Verel,Sébastien, Moczygemba,Isabelle, Schiex,Thomas, Simoncini,David, Bahl,ChristopherD]
通讯作者: Bahl,ChristopherD
海外基金